Pulse Biosciences (NASDAQ:PLSE) Sees Unusually-High Trading Volume – Still a Buy?

Pulse Biosciences, Inc (NASDAQ:PLSE) shares saw unusually-strong trading volume on Monday . Approximately 771,664 shares changed hands during mid-day trading, an increase of 150% from the previous session’s volume of 308,746 shares.The stock last traded at $20.2650 and had previously closed at $19.08.

Analysts Set New Price Targets

Several analysts have commented on PLSE shares. Wall Street Zen raised Pulse Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, February 21st. Mizuho set a $30.00 price objective on Pulse Biosciences in a report on Friday, February 6th. Oppenheimer reissued an “outperform” rating and issued a $30.00 price objective on shares of Pulse Biosciences in a report on Friday, February 20th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $30.00.

Pulse Biosciences Price Performance

The stock has a market cap of $1.30 billion, a PE ratio of -17.35 and a beta of 1.63. The stock has a 50-day moving average of $20.85 and a 200 day moving average of $17.59.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings data on Monday, May 4th. The company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.05. The company had revenue of $0.40 million for the quarter, compared to analysts’ expectations of $0.25 million. Research analysts forecast that Pulse Biosciences, Inc will post -1.29 EPS for the current fiscal year.

Insider Buying and Selling

In other Pulse Biosciences news, insider Kevin Patrick Danahy sold 5,000 shares of Pulse Biosciences stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $23.64, for a total value of $118,200.00. Following the sale, the insider owned 43,298 shares in the company, valued at $1,023,564.72. The trade was a 10.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 65,000 shares of company stock valued at $1,565,400 in the last quarter. 74.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Pulse Biosciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets raised its position in Pulse Biosciences by 63.6% in the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock valued at $26,000 after purchasing an additional 680 shares during the period. Tower Research Capital LLC TRC raised its position in Pulse Biosciences by 275.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock valued at $44,000 after purchasing an additional 2,156 shares during the period. Russell Investments Group Ltd. raised its position in Pulse Biosciences by 13.8% in the fourth quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock valued at $70,000 after purchasing an additional 619 shares during the period. KLP Kapitalforvaltning AS raised its position in Pulse Biosciences by 136.0% in the third quarter. KLP Kapitalforvaltning AS now owns 5,900 shares of the company’s stock valued at $104,000 after purchasing an additional 3,400 shares during the period. Finally, The Manufacturers Life Insurance Company purchased a new stake in Pulse Biosciences in the second quarter valued at $158,000. Hedge funds and other institutional investors own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.